References
- Cools J, Stover E H, Wlodarska I, Marynen P, Gilliland D G. The FIP1L1-PDGFRalpha kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia. Curr Opin Hematol 2004; 11: 51–57
- Cools J, DeAngelo D J, Gotlib J, Stover E H, Legare R D, Cortes J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003; 348: 1201–1214
- Chusid M J, Dale D C, West B C, Wolff S M. The hypereosinophilic syndrome: analysis of 14 cases with review of the literature. Medicine (Baltimore) 1975; 54: 1–27
- Bain B, Pierre R, Imbert M, Vardiman J W, Brunning R D, Flandrin G. Chronic eosinophilic leukemia and the hypereosinophilic syndrome. WHO classification of tumours of haematopoietic and lymphoid tissues, E Jaffe, N Harris, H Stein, J W Vardiman. IARC Press, International Agency for Research on Cancer, Lyon, France 2001; 29–34
- Apperley J, Bain B. The FIP1L1–PDGFRA syndrome: a case of mistaken identity. Blood 2004; 104: 2999–3000
- Pardanani A, Brockman S R, Paternoster S F, Flynn H C, Ketterling R P, Lasho T L, et al. FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood 2004; 104: 3038–3045
- Apperley J F, Gardembas M, Melo J V, Russell-Jones R, Bain B J, Baxter E J, et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 2002; 347: 481–487
- Steer E J, Cross N C. Myeloproliferative disorders with translocations of chromosome 5q31–35: role of the platelet-derived growth factor receptor Beta. Acta Haematol 2002; 107: 113–122
- Kantarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Verstovsek S, Giles F, et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 2004; 103: 2873–2878
- Druker B J, David A. Karnofsky Award lecture. Imatinib as a paradigm of targeted therapies. J Clin Oncol 2003; 21(Suppl 3)239S–245S
- Gotlib J, Cools J, Malone J M, 3rd, Schrier S L, Gilliland D G, Coutre S E. The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. Blood 2004; 103: 2879–2891
- Wolf D, Gastl G, Rumpold H. [Complete remission of an idiopathic hypereosinophilic syndrome while using imatinib]. Dtsch Med Wochenschr 2004; 129: 2104–2106
- Schaller J L, Burkland G A. Case report: rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate. Med Gen Med 2001; 3: 9
- Fujii N, Ikeda K, Takahashi N, Kojima K, Kobayashi Y, Ashiba A, et al. Multilineage involvement in hypereosinophilic syndrome terminating in granulocytic sarcoma and leukaemic transformation with trisomy 8. Br J Haematol 2002; 119: 716–719
- Guitard A M, Horschowski N, Mozziconacci M J, Michel G, George F, Capodano A M, et al. Hypereosinophilic syndrome in childhood: trisomy 8 and transformation to mixed acute leukaemia. Nouv Rev Fr Hematol 1994; 35: 555–559
- Kobayashi M, Katayama T, Ochiai S, Yoshida M, Kaito K, Masuoka H, et al. [Interferon-alpha therapy in the myeloproliferative variants of hypereosinophilic syndrome]. Rinsho Ketsueki 1993; 34: 367–372
- Lynott A, Ravandi-Kashani F, Giles F J. Malignancy: case report: hypereosinophilia progressing to granulocytic sarcoma and acute myelocytic leukemia with trisomy 8: a case report and review of the literature. Hematology 2000; 4: 487–493
- Quiquandon I, Claisse J F, Capiod J C, Delobel J, Prin L. alpha-Interferon and hypereosinophilic syndrome with trisomy 8: karyotypic remission. Blood 1995; 85: 2284–2285
- Salem Z, Zalloua P A, Chehal A, Bitar N, Abboud M, Kadri A, et al. Effective treatment of hypereosinophilic syndrome with imatinib mesylate. Hematol J 2003; 4: 410–412
- Anghel G, De Rosa L, Ruscio C, Petti N, Riccardi M, Severino A, et al. Efficacy of imatinib mesylate in a patient with idiopathic hypereosinophilic syndrome and severe heart involvement. Tumori 2005; 91: 67–70
- Lefebvre C, Bletry O, Degoulet P, Guillevin L, Bentata-Pessayre M, Le Thi Huong D, et al. [Prognostic factors of hypereosinophilic syndrome. Study of 40 cases]. Ann Med Interne (Paris) 1989; 140: 253–257